Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model

European Journal of Pharmacology

Volumn 366, Issue 2-3, 1999, Pages 203-213

  Huang, Jinbao ^a   Rebello, Sam S ^a   Rosenberg, Lewis A ^a   Kaneko, Munekiyo ^b   Sakurama, Teruo ^b   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Coronary artery thrombosis; GPIIb IIIa receptor antagonist; Myocardial infarction; Platelet aggregation; SM 20302

Indexed keywords

3 [3 (4 AMIDINOBENZAMIDO)PROPIONAMIDO] 2 (4 ETHYLBENZENESULFONAMIDO)PROPIONIC ACID; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; HEART INFARCTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM;

ANIMALS; BENZENE DERIVATIVES; BLOOD CELL COUNT; BLOOD PLATELETS; CHRONIC DISEASE; CORONARY CIRCULATION; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES;

EID: 0033038383     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00912-1     Document Type: Article

References (44)

1. Adgey A.A.J. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am. Heart J. 135:1998;S43-S55.
2. Barrett J.S., Murphy G., Peerlinck K., De Lepeleire I., Gould R.J., Panebianco D., Hand E., Deckmyn H., Vermylen J., Arnout J. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men. Clin. Pharmacol. Ther. 56:1994;377-388.
3. Bates E.R., Walsh D.G., Mu D.X., Abrams G.D., Lucchesi B.R. Sustained inhibition of the vessel wall-platelet interaction after deep coronary artery injury by temporary inhibition of the platelet glycoprotein IIb/IIIa receptor. Coron. Artery Dis. 3:1992;67-76.
4. Channing-Rodgers R.P., Levin J. A critical reappraisal of the bleeding time. Semin. Thromb. Hemost. 16:1990;1-20.
5. Charo I.F., Scarborough R.M., DuMee C.P., Wolf D., Phillips D.R., Swift R.L. Pharmacodynamics of the GPIIb-IIIa antagonist integrilin: phase I clinical studies in normal healthy volunteers. Circulation. 86:1992;I260. (abstract).
6. Coller B.S. Monitoring platelet GPIIb/IIIa receptor antagonist therapy. Circulation. 96:1997;3828-3832.
7. D'souza S.E., Haas T.A., Piotrowicz R.S., Byers-Ward V., McGrath D.E., Soule H.R., Cierniewski C., Plow E.F., Smith J.W. Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: cation displacement is involved in ligand binding. Cell. 79:1994;659-667.
8. EPIC Investigators Evaluation of a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor for preventing ischemic complications of high-risk angioplasty. N. Engl. J. Med. 330:1994;956-961.
9. EPIC Investigators Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis. Lancet. 343:1994;881-886.
10. Fitzgerald D.J., Roy L., Catella F., Fitzgerald G.A. Platelet activation in unstable coronary artery disease. N. Engl. J. Med. 315:1986;983-989.
11. Gold H.K., Gimple L.W., Yasuda T., Leinbach R.C., Werner W., Holt R., Jordan R., Berger H., Collen D., Coller B.S. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J. Clin. Invest. 86:1990;651-659.
12. Groves H.M., Kilough-Rathbone R.L., Richardson M., Moore S., Mustard J.F. Platelet interaction with damaged rabbit aorta. Lab. Invest. 40:1979;194-200.
13. Groves H.M., Kilough-Rathbone R.L., Mustard J.F. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis. 6:1986;189-195.
14. Heidenreich R., Eisman R., Delgrosso K., Surrey S., Bennett J.S., Schwartz E., Poncz M. Organization of the gene for platelet glycoprotein IIb. Biochemistry. 29:1990;1232-1244.
15. 2+ binding site on the beta 3 integrins that regulates the dissociation rate for RGD ligands. J. Biol. Chem. 271:1996;21745-21751.
16. IMPACT-AMI Investigators Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation. 95:1997;846-854.
17. Kieffer N., Phillips D.R. Platelet membrane glycoproteins: functions in cellular interactions. Annu. Rev. Cell. Biol. 6:1990;329-357.
18. Kleiman N.S., Raizner A.E., Jordan R., Wang A.L., Norton D., Mace K.F., Joshi A., Coller B.S., Weisman H.F. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J. Am. Coll. Cardiol. 26:1995;1665-1671.
19. Lam S.C. Isolation and characterization of a chymotryptic fragment of platelet glycoprotein IIb/IIIa retaining Arg-Gly-Asp binding activity. J. Biol. Chem. 267:1992;5649-5655.
20. Lanza F., Stierle A., Gachet C., Cazenave J.P. Differential effects of extra- and intracellular calcium chelation on human platelet function and glycoprotein IIb/IIIa complex stability. Nouv. Rev. Fr. Hematol. 34:1992;123-131.
21. Lee J.O., Rieu P., Arnaout M.A., Liddington R. Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell. 80:1995;631-638.
22. Loftus J.C., O'Toole T.E., Plow E.F., Glass A., Frelinger A.L., Ginsberg M.H. A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science. 249:1990;915-918.
23. Lucchesi B.R., Rote W.E., Driscoll E.M., Mu D.X. Prevention of thrombosis and rethrombosis and enhancement of the thrombotic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist. Br. J. Pharmacol. 113:1994;1333-1343.
24. Marguerie G.A., Plow E.F., Edgington T.S. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J. Biol. Chem. 254:1979;5357-5363.
25. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., Jordan R.E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation. 97:1998;1680-1688.
26. Mickelson J.K., Simpson P.J., Lucchesi B.R. Antiplatelet monoclonal F(ab′)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J. Mol. Cell. Cardiol. 21:1989;393-405.
27. Mulvihill J.N., Faradji A., Oberling F., Cazenave J.P. Surface passivation by human albumin of plasmapheresis circuits reduces platelet accumulation and thrombus formation. Experimental and clinical studies. J. Biomed. Mater. Res. 24:1990;155-163.
28. Peerschke E.I., Zucker M.B., Grant R.A., Egan J.J., Johnson M.M. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood. 55:1980;841-847.
29. Phillip, R.B., 1981. In vitro tests of platelet function and platelet-inhibition drugs. In: Phillip, R.B. (Ed), Methods of Testing Proposed Antithrombotic Drugs. CRC Press, Boca Raton, FL, pp. 129-169.
30. 2+ on GPIIb/IIIa interactions with integrilin: enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 96:1997;1488-1494.
31. Rebello S.S., Driscoll E.M., Lucchesi B.R. TP-9201, a glycoprotein IIb/IIIa receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke. 28:1997;1-8.
32. Rebello S.S., Huang J., Saito K., Lucchesi B.R. The in vivo efficacy of SM-20302, a GPIIb/IIIa receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterioscler. Thromb. Vasc. Biol. 18:1998;954-960.
33. Rebello S.S., Huang J., Shiu W.J., Saito K., Munekiyo K., Saitoh Y., Lucchesi B.R. Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. J. Cardiovasc. Pharmacol. 32:1998;485-494.
34. Rebello, S.S., Huang, J., Faul, J.D., Lucchesi, B.R., 1999. In vitro assessment of GPIIb/IIIa receptor antagonists and the role of ionized calcium. J. Thromb. Thrombolysis (accepted).
35. RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
36. Romson J.L., Haack D.W., Lucchesi B.R. Electrical induction of coronary thrombosis in the ambulatory canine: a model for in vivo evaluation. Thromb. Res. 17:1980;841-853.
37. Rote W.E., Werns S.W., Davis J.H., Feigen L.P., Kilgore K.S., Lucchesi B.R. Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery. Cardiovasc. Res. 27:1993;500-507.
38. Rote W.E., Mu D.X., Bates E.R., Nedelman M.A., Lucchesi B.R. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model: I. Adjunctive therapy with monoclonal antibody 7E3 F(ab′)2 fragment. J. Cardiovasc. Pharmacol. 23:1994;194-202.
39. Rubenstein M.D., Wall R.T., Bain D.S., Harrison D.C. Platelet activation in clinical coronary artery disease and spasm. Am. Heart J. 102:1981;363-367.
40. Sakurama T., Horisawa S., Kurata H., Kishimoto H., Nakano M., Fukuoka T., Kohda A., Kaneko M. SM-20302, a novel GPIIb/IIIa receptor antagonist, has shown a selective antithrombotic activity without increasing the risk of hemorrhage in vivo. Thromb. Haemost. 77:1997;7. (abstract).
41. Schneider D.J., Tracy P.B., Mann K.G., Sobel B.E. Differential effects of anticoagulants on the activation of platelets in vivo. Circulation. 96:1997;2877-2883.
42. +2-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb-IIIa complex. J. Biol. Chem. 264:1989;13102-13108.
43. Sudo Y., Kilgore K.S., Lucchesi B.R. Monoclonal antibody [7E3 F(ab′)2] prevents arterial but not venous rethrombosis. J. Cardiovasc. Pharmacol. 26:1995;241-250.
44. Tozer E.C., Liddington R.C., Sutcliffe M.J., Smeeton A.H., Loftus J.C. Ligand binding to integrin alpha IIb beta 3 is dependent on a MIDAS-like domain in the beta 3 subunit. J. Biol. Chem. 271:1996;21978-21984.